Intercept Pharmaceuticals, Inc. logo
Intercept Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Business Update
May 06, 2021 07:00 ET | Intercept Pharmaceuticals, Inc.
Worldwide Ocaliva® net sales of $81.7M, representing 12% growth over the prior year quarter Company narrows 2021 financial guidance; now expects worldwide Ocaliva net sales guidance of $325 million...
Intercept Pharmaceuticals, Inc. logo
Intercept to Announce First Quarter 2021 Financial Results on May 6, 2021
April 26, 2021 08:00 ET | Intercept Pharmaceuticals, Inc.
NEW YORK, April 26, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to...
Intercept Pharmaceuticals, Inc. logo
Intercept Announces Departure of Chief Financial Officer
March 10, 2021 08:00 ET | Intercept Pharmaceuticals, Inc.
Rocco Venezia Appointed Chief Accounting Officer and Acting CFO -Intercept Reiterates 2021 Financial Guidance - NEW YORK, March 10, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc....
Intercept Pharmaceuticals, Inc. logo
Intercept Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results, Issues 2021 Financial Guidance and Provides Business Update
February 25, 2021 07:00 ET | Intercept Pharmaceuticals, Inc.
Worldwide Ocaliva® net sales of $83.3 million and $312.7 million for the fourth quarter and full year 2020, representing 18% and 25% growth over the prior year Intercept provides initial 2021...
Intercept Pharmaceuticals, Inc. logo
Intercept Appoints Dagmar Rosa-Bjorkeson to Its Board of Directors
February 23, 2021 08:00 ET | Intercept Pharmaceuticals, Inc.
NEW YORK, Feb. 23, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat...
Intercept Pharmaceuticals, Inc. logo
Intercept to Present at Upcoming Investor Conferences
February 19, 2021 08:00 ET | Intercept Pharmaceuticals, Inc.
NEW YORK, Feb. 19, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat...
Intercept Pharmaceuticals, Inc. logo
Intercept Appoints Linda Richardson as Chief Commercial Officer
February 17, 2021 08:00 ET | Intercept Pharmaceuticals, Inc.
Lisa DeFrancesco, Senior Vice President, Corporate Affairs & Investor Relations, will join Intercept’s Executive Leadership Team NEW YORK, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Intercept...
Intercept Pharmaceuticals, Inc. logo
Intercept to Announce Fourth Quarter and Full Year 2020 Financial Results on February 25, 2021
February 11, 2021 08:00 ET | Intercept Pharmaceuticals, Inc.
NEW YORK, Feb. 11, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat...
Intercept Pharmaceuticals, Inc. logo
Intercept Company Statement on Analyst Note
January 27, 2021 13:35 ET | Intercept Pharmaceuticals, Inc.
NEW YORK, Jan. 27, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat...
Intercept Pharmaceuticals, Inc. logo
Intercept Appoints Jared M. Freedberg as General Counsel and Secretary
January 11, 2021 08:00 ET | Intercept Pharmaceuticals, Inc.
NEW YORK, Jan. 11, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat...